Genelux
phase anti tumor activity as leading into combination regimen prior prior | Genelux
Company
Deck Type
Sector
Industry
Deck date
October 2023
Slide
11 of 38
Similar slides by Genelux
See diffirences between slides (animation)
Investor Presentation
February 2024
phase anti tumor activity as leading into combination soc aurelia regimen gratis | Genelux
Investor Presentation
December 2023
phase anti tumor activity as leading into combination a | Genelux
Investor Presentation
July 2023
phase anti tumor activity as leading into combination platinum resistant | Genelux
Related slides by other companies
Checkmate Pharmaceuticals
IPO
August 2020
activity supportive of further development in combination subjects responded i therapy checkmate | Checkmate Pharmaceuticals
Kymera
Investor Presentation
June 2023
objectives a a | Kymera
Kymera
Investor Presentation
August 2023
objectives a a | Kymera
BioNTech
Results
November 2020
phase a anti tumor activity in immune recurrent refractory expansion | BioNTech
Other recent decks by Genelux
See all presentations (4 decks)
Investor Presentation
February 2024
Investor Presentation
December 2023
Investor Presentation
July 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io